Cynvenio and Saint Luke’s Cancer Institute Launch Pilot Study to Evaluate the Potential for Early Detection of Recurrent Breast Cancer Following Therapy

August 17, 2017 – Cynvenio Biosystems, Inc. announced the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri. The study’s goal is to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) cell testing in patients at high-risk of relapse after neoadjuvant chemotherapy.

Cynvenio Announces New Deployment of LiquidBiopsy® System at 
Leading Cancer Research Center in South Korea

July 27, 2017 – Cynvenio announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.

Cynvenio’s LiquidBiopsy® Platform-Derived Research Data to be Presented at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois

June 1, 2017 – Cynvenio's LiquidBiopsy rare cell and cell-free isolation platform will be featured at the 2017 ASCO Annual Meeting at booth #23123. Also at the conference, study data collected via the LiquidBiopsy platform and supporting the utility of longitudinal monitoring of breast cancer patients will be published. 

Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients

May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.

Cynvenio Clinical Trial Data Supports Benefits of Multi-Template Liquid Biopsy Sequencing for Cancer Mutational Profiling

April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.

Genome Web: Mt. Sinai Studying CTCs, ctDNA in Context of Triple Negative Breast Cancer

April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.

Cynvenio Announces Availability of Concordia, a New Cell-free DNA Purification Upgrade for its LiquidBiopsy Whole Blood Enrichment Platform

February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.

Cynvenio and ATGen Open Recruitment for New LiquidBiopsy Clinical Research Study in Triple Negative Breast Cancer

December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.